Allianz Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.01M | Sell |
3,900
-1,500
| -28% | -$1.15M | ﹤0.01% | 1394 |
|
|
2025
Q4 | $4.17M | Buy |
5,400
+1,500
| +38% | +$1.02M | ﹤0.01% | 1219 |
|
|
2025
Q3 | $2.19M | Sell |
3,900
-3,200
| -45% | -$1.81M | ﹤0.01% | 1465 |
|
|
2025
Q2 | $3.73M | Sell |
7,100
-400
| -5% | -$223K | ﹤0.01% | 1237 |
|
|
2025
Q1 | $4.76M | Sell |
7,500
-2,100
| -22% | -$1.44M | 0.01% | 1142 |
|
|
2024
Q4 | $6.84M | Buy |
9,600
+200
| +2% | +$168K | 0.01% | 905 |
|
|
2024
Q3 | $9.88M | Buy |
9,400
+400
| +4% | +$445K | 0.01% | 747 |
|
|
2024
Q2 | $9.46M | Buy |
9,000
+2,500
| +38% | +$2.42M | 0.01% | 708 |
|
|
2024
Q1 | $6.26M | Sell |
6,500
-3,700
| -36% | -$3.52M | 0.01% | 794 |
|
|
2023
Q4 | $8.96M | Sell |
10,200
-2,200
| -18% | -$1.81M | 0.01% | 719 |
|
|
2023
Q3 | $10.2M | Sell |
12,400
-3,700
| -23% | -$2.91M | 0.02% | 719 |
|
|
2023
Q2 | $11.6M | Buy |
16,100
+5,900
| +58% | +$4.55M | 0.02% | 603 |
|
|
2023
Q1 | $8.38M | Buy |
10,200
+7,800
| +325% | +$5.88M | 0.01% | 761 |
|
|
2022
Q4 | $1.73M | Buy |
2,400
+2,200
| +1,100% | +$1.62M | ﹤0.01% | 1330 |
|
|
2022
Q3 | $138K | Sell |
200
-400
| -67% | -$252K | ﹤0.01% | 1656 |
|
|
2022
Q2 | $355K | Sell |
600
-400
| -40% | -$260K | ﹤0.01% | 1972 |
|
|
2022
Q1 | $698K | Buy |
1,000
+400
| +67% | +$253K | ﹤0.01% | 2007 |
|
|
2021
Q4 | $379K | Sell |
600
-2,700
| -82% | -$1.66M | ﹤0.01% | 2303 |
|
|
2021
Q3 | $2M | Buy |
3,300
+2,400
| +267% | +$1.49M | ﹤0.01% | 1659 |
|
|
2021
Q2 | $503K | Buy |
+900
| New | +$456K | ﹤0.01% | 2033 |
|
|
2020
Q3 | – | Sell |
-11,100
| Closed | -$6.92M | – | 2305 |
|
|
2020
Q2 | $6.92M | Buy |
11,100
+7,000
| +171% | +$3.97M | 0.01% | 1050 |
|
|
2020
Q1 | $2M | Sell |
4,100
-2,400
| -37% | -$990K | ﹤0.01% | 1527 |
|
|
2019
Q4 | $2.44M | Buy |
6,500
+2,300
| +55% | +$774K | ﹤0.01% | 1781 |
|
|
2019
Q3 | $1.17M | Buy |
4,200
+3,400
| +425% | +$1.01M | ﹤0.01% | 2064 |
|
|
2019
Q2 | $250K | Sell |
800
-100
| -11% | -$33.3K | ﹤0.01% | 2550 |
|
|
2019
Q1 | $370K | Buy |
+900
| New | +$371K | ﹤0.01% | 2404 |
|
|
2018
Q4 | – | Sell |
-2,800
| Closed | -$1.13M | – | 2681 |
|
|
2018
Q3 | $1.13M | Buy |
2,800
+200
| +8% | +$76.1K | ﹤0.01% | 2181 |
|
|
2018
Q2 | $897K | Buy |
2,600
+400
| +18% | +$125K | ﹤0.01% | 2267 |
|
|
2018
Q1 | $758K | Sell |
2,200
-10,900
| -83% | -$3.79M | ﹤0.01% | 2289 |
|
|
2017
Q4 | $4.92M | Buy |
13,100
+2,100
| +19% | +$850K | ﹤0.01% | 1627 |
|
|
2017
Q3 | $4.92M | Buy |
11,000
+5,000
| +83% | +$2.38M | ﹤0.01% | 1625 |
|
|
2017
Q2 | $2.95M | Sell |
6,000
-5,400
| -47% | -$2.36M | ﹤0.01% | 1843 |
|
|
2017
Q1 | $4.42M | Buy |
11,400
+100
| +0.9% | +$37.1K | ﹤0.01% | 1675 |
|
|
2016
Q4 | $4.15M | Buy |
11,300
+4,400
| +64% | +$1.67M | ﹤0.01% | 1710 |
|
|
2016
Q3 | $2.77M | Sell |
6,900
-3,700
| -35% | -$1.48M | ﹤0.01% | 1859 |
|
|
2016
Q2 | $3.7M | Buy |
10,600
+4,100
| +63% | +$1.58M | ﹤0.01% | 1643 |
|
|
2016
Q1 | $2.34M | Buy |
6,500
+1,900
| +41% | +$783K | ﹤0.01% | 1738 |
|
|
2015
Q4 | $2.5M | Buy |
4,600
+3,900
| +557% | +$2.11M | ﹤0.01% | 1624 |
|
|
2015
Q3 | $326K | Hold |
700
| – | – | ﹤0.01% | 2178 |
|
|
2015
Q2 | $357K | Hold |
700
| – | – | ﹤0.01% | 2208 |
|
|
2015
Q1 | $316K | Sell |
700
-1,000
| -59% | -$424K | ﹤0.01% | 2101 |
|
|
2014
Q4 | $697K | Buy |
+1,700
| New | +$669K | ﹤0.01% | 1917 |
|
Other funds holding REGN
VCM
N
Allianz Asset Management's REGN Position: Q1 2026 in Review
Allianz Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 79% in Q1 2026, buying an estimated $102M and bringing the position to 301,196 shares worth $233M. The position accounts for 0.24% of the portfolio, ranked #77.
Allianz Asset Management first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Allianz Asset Management held 301,196 shares of Regeneron Pharmaceuticals worth $233M as of Q1 2026.
- Allianz Asset Management bought 132,582 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $102M.
- Regeneron Pharmaceuticals made up 0.24% of Allianz Asset Management's portfolio in Q1 2026, its #77 holding.
- Allianz Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.